Company Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease.
It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite.
Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 2, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Esther Rajavelu |
Contact Details
Address: 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 United States | |
| Phone | (857) 242-1600 |
| Website | sperotherapeutics.com |
Stock Details
| Ticker Symbol | SPRO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001701108 |
| CUSIP Number | 84833T103 |
| ISIN Number | US84833T1034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Esther P. Rajavelu | Chief Executive Officer, Chief Financial Officer, President and Treasurer |
| Dr. Ankit Mahadevia M.D., MBA | Co-Founder and Director |
| Timothy Keutzer | Chief Operating Officer |
| John Raymond | Senior Vice President of Finance and Business Operations |
| Dr. David Hong | Senior Vice President of Clinical Development |
| Sheila Finan | Senior Vice President of Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 8-K | Current Report |
| Mar 28, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | 8-K | Current Report |